NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Scribe Therapeutics SCTX

Scribe Therapeutics listed on Nasdaq on 27 Jul 2026 and is not in the S&P 500. It is worth $250 million. Its price history starts on 31 Jul 2026. Its board is not in our data yet.

CEO
Benjamin L. Oakes
Listed
27 Jul 2026 on Nasdaq, IPO filings and terms
Headquarters
Alameda, CA
Market cap
$250M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Scribe Therapeutics' quarterly filings.

Quarters since Jun 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jun 2025 to Sep 2026

$0$10M$20M$30M20252026$2M

Scribe Therapeutics' market cap since July 2026

Weekly, up to 13 Nov 2026

Aug 2026SepOctNov$310M

Board and leadership

Board and officers

Scribe Therapeutics' board is not in our data yet. It listed on 27 Jul 2026 and has not filed a proxy statement. See its 8-K filings.

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $51.3 million in 5 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
28 Jul 2026BuyBehzad AghazadehDirectorDirectorBuy7,905$144K
27 Jul 2026BuyCarl L. GordonDirectorDirectorBuy1,000,000$15M
24 Jul 2026BuyBehzad AghazadehDirectorDirectorBuy2,383,333$36M
23 Jul 2026BuySvetlana LucasChief Business OfficerChief Business OfficerBuy3,000$45K
23 Jul 2026BuyDavid ParrotChief Financial OfficerChief Financial OfficerBuy2,666$40K

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Scribe Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.